Fig. 1: Response rates in all patients and lenalidomide-refractory patients treated with D-Kd in PLEIADES or EQUULEUS. | Blood Cancer Journal

Fig. 1: Response rates in all patients and lenalidomide-refractory patients treated with D-Kd in PLEIADES or EQUULEUS.

From: Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS

Fig. 1

Data were shown for the all-treated population. Note: Due to rounding, percentages may not add up to the total percentage for each category. CR complete response, D-Kd daratumumab/carfilzomib/dexamethasone, ORR overall response rate, PR partial response, sCR stringent complete response, VGPR very good partial response.

Back to article page